ONL THERAPEUTICS
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.
ONL THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Ann Arbor, Michigan, United States
Country:
United States
Website Url:
http://www.onltherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
734-926-5530
Email Addresses:
[email protected]
Total Funding:
57.94 M USD
Technology used in webpage:
SPF Pound Sterling Japanese Yen Oracle Cloud Campaign Monitor Widget
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bios Partners
Bios Partners investment in Series B - ONL Therapeutics
PSQ Capital
PSQ Capital investment in Series B - ONL Therapeutics
InFocus Capital Partners
InFocus Capital Partners investment in Series B - ONL Therapeutics
MINTS
MINTS investment in Series B - ONL Therapeutics
Grand Angels
Grand Angels investment in Series B - ONL Therapeutics
Kaitai Capital
Kaitai Capital investment in Series B - ONL Therapeutics
Biosciences Research and Commercialization Center (BRCC)
Biosciences Research and Commercialization Center (BRCC) investment in Series B - ONL Therapeutics
Capital Community Angel Investors
Capital Community Angel Investors investment in Series B - ONL Therapeutics
ExSight Ventures
ExSight Ventures investment in Series B - ONL Therapeutics
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC investment in Series B - ONL Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-09 | ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer |
Official Site Inspections
http://www.onltherapeutics.com
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ONL Therapeutics"
About - ONL Therapeutics
ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future Our Mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases …See details»
Our Team - ONL Therapeutics
About Our Team ONL’s team is comprised of experienced and successful life science industry executives and world-renowned thought leaders in relevant fields of ocular disease research. ONL Interns Developing the next generation of …See details»
ONL Therapeutics - Crunchbase Company Profile
Organization. ONL Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number 734-926-5530; ONL Therapeutics …See details»
ONL Therapeutics - LinkedIn
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the ...See details»
ONL Therapeutics Company Overview, Contact Details
Mar 08, 2023 | www.onltherapeutics.com ONL Therapeutics, Inc. hired Sushanta Mallick as Chief Development Officer on Feb 9th '22. ONL Therapeutics, Inc., a clinical-stage …See details»
ONL Therapeutics - VentureRadar
Develops therapeutics to protect and improve the vision of patients with retinal disease. " ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting …See details»
ONL Therapeutics, Inc.
For more information about ONL Therapeutics, please visit www.onltherapeutics.com. Phase 1 Phase 2 Orphan Drug Clinical Result. 100 Deals associated with ONL Therapeutics, Inc. Login …See details»
ONL Therapeutics - Overview, News & Similar companies
Mar 8, 2023 ONL Therapeutics contact info: Phone number: (734) 412-8787 Website: www.onltherapeutics.com What does ONL Therapeutics do? Founded in 2011, ONL …See details»
ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of …See details»
About - ONL Therapeutics
Technical storage or access that is used strictly for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of …See details»
ONL Therapeutics - Craft
ONL Therapeutics has 5 employees at their 1 location and $57.02 m in total funding,. See insights on ONL Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
ONL Therapeutics Names Connie Chang as Chief Operating
Jan 19, 2021 Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related …See details»
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series
Jan 13, 2022 For more information about ONL Therapeutics, please visit www.onltherapeutics.com. Company Contact: Linda Kemnitz ONL Therapeutics, Inc. …See details»
Contact - ONL Therapeutics
Contact View our research FCOI policy Notice Regarding Employer Impersonation Job Scams: Recently, we have become aware of several instances of employer impersonation job scams …See details»
ONL Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire
Feb 1, 2023 First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells. February 01, 2023 07:00 ET | Source: …See details»
AmbioPharm Supports ONL Therapeutics with Peptide …
Jul 12, 2022 Press Release. NORTH AUGUSTA, S.C. and ANN ARBOR, Mich., July 12, 2022 – AmbioPharm, a global peptide CDMO, is a key partner in peptide manufacturing and …See details»
Clinical Trials - ONL Therapeutics
ONL is leveraging its innovative neuroprotection platform technology to develop new treatments for multiple, vision-threatening retinal diseases ONL’s lead therapeutic candidate, ONL1204, is …See details»
Recommended Stories
Dec 22, 2020 Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 …See details»
News - ONL Therapeutics
Feb 13, 2023 ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal DetachmentSee details»